Pfizer is a leading global pharmaceutical company focusing its activities on meeting the most important medical needs in key therapeutic areas. Pfizer's goal is not only to develop new drugs - it considers the challenges of medicine in a broader context, transcends the medical realm, provides information, education and support to help patients gain access to the treatments they need and apply them to the best results, believing that health cooperation is key to accelerating the pace of innovation. Innovative solutions contribute primarily to extending and improving the quality of life of patients. The benefits of this, however, are much broader, as they cover a macro scale: greater productivity, i.e. higher income from work, and lower social costs for the health care system.
Pfizer offers prescription medicinal products on the Polish market, including modern biological drugs, vaccines and oncology drugs, as well as over-the-counter products and dietary supplements. The company invests in therapeutic areas that require special attention for medical reasons. The company's main areas of interest are oncology, vaccines, rare diseases, inflammatory diseases and immunology, cardiovascular and metabolic diseases and pain management. In June 2017, Pfizer launched in Warsaw an international platform supporting the monitoring of adverse drug reactions (Drug Safety Unit Platform) in Europe, Africa and the Middle East. The Pfizer company and its activities are appreciated by the environment, as evidenced by the awards and titles received, including: Executive Club Responsible Business Awards 2016 in the "Outstanding CSR project" category, Innovation Eagle 2017 and 2016 Leader for the HTbox application in the "Medicine and Pharmacy" category in the technology competition "Lider 2016" organized by "Gazeta Bankowa", Silver Leader of Healthcare 2017 OSOZ in the category "Innovative Ideas" for the educational portal Akademia Dobrego Pharmacuty, Friend of Polish Cardiology 2016.